In 2015, Johnson & Johnson announced a first-of-its-kind pilot partnership between Johnson & Johnson Innovative Medicine and the Division of Medical Ethics at New York University (NYU) Langone Health to form the Compassionate Use Advisory Committee (CompAC). This model is a novel approach that Johnson & Johnson employs globally to provide a fair, ethical evaluation of compassionate use requests for specific investigational medicines for patients with serious or life-threatening diseases.
CompAC, comprised of ethicists, physicians and patient representatives independently selected by NYU, provides recommendations to J&J IM on preapproval access plans and individual requests received at J&J IM. CompAC affirms Johnson & Johnson’s commitment to ensuring a transparent, ethical and objective approach to reviewing compassionate use requests.
Click here for information on CompAC’s 10 year anniversary.
Below is an infographic illustrating the key results from our first CompAC pilot program.
